Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

6 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 4
6(100.0%)
6Total
Phase 4(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06423235Phase 4Recruiting

Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules

Role: lead

NCT06159114Phase 4Completed

Efficacy and Safety of Ningmitai Capsule Alone or Combined With Celecoxib in the Treatment of CP/CPPS

Role: lead

NCT06105827Phase 4Completed

Clinical Study of Ningmitai Capsule on Promoting the Passage of Residual Fragments After Ureteroscopic Lithotripsy

Role: lead

NCT06064448Phase 4Completed

Clinical Observation of Ningmitai Capsule in Treating Chronic Pelvic Pain Syndrome With Erectile Dysfunction

Role: lead

NCT05890235Phase 4Completed

Efficacy and Safety of Ningmitai Capsule in Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Role: lead

NCT05551221Phase 4Recruiting

The Efficacy and Safety of Silodosin Singly or Combined With Ningmitai Capsules in the Treatment of Benign Prostatic Hyperplasia

Role: lead

All 6 trials loaded